Showing results (321-330 of 494) with videos related to
Sort By:
Pageof 50
Nature Communications|July 15, 2024
A combination treatment based on drug repurposing demonstrates mutation-agnostic efficacy in pre-clinical retinopathy modelsHenri Leinonen, Jianye Zhang, Laurence M Occelli, et al.Annals of Surgery|September 27, 2023
New Sarculator Prognostic Nomograms for Patients With Primary Retroperitoneal Sarcoma: Case Volume Does MatterDario Callegaro, Francesco Barretta, Chandrajit P Raut, et al.Journal for Immunotherapy of Cancer|November 18, 2020
Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective studyPiotr Rutkowski, Alice Indini, Matilde De Luca, et al.European Journal of Cancer (Oxford, England : 1990)|January 19, 2021
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trialRobin L Jones, César Serrano, Margaret von Mehren, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 TrialCeleste Lebbé, Nicolas Meyer, Laurent Mortier, et al.Cancers|June 22, 2023
The Current Treatment Trends and Survival Patterns in Melanoma Patients with Positive Sentinel Lymph Node Biopsy (SLNB): A Multicenter Nationwide StudyMarcin Ziętek, Paweł Teterycz, Jędrzej Wierzbicki, et al.Clinical Sarcoma Research|September 22, 2016
Current status and unanswered questions on the use of Denosumab in giant cell tumor of boneCzar Louie Gaston, Robert J Grimer, Michael Parry, et al.European Journal of Cancer (Oxford, England : 1990)|December 22, 2019
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trialsAxel Hauschild, Paolo A Ascierto, Dirk Schadendorf, et al.Cancers|May 14, 2022
Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma PatientsPaweł Rogala, Anna M Czarnecka, Bożena Cybulska-Stopa, et al.The Lancet. Respiratory Medicine|April 20, 2018
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trialPatrick Schöffski, Jozef Sufliarsky, Hans Gelderblom, et al.Pageof 50